# Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation

> **NCT01483183** · PHASE1 · TERMINATED · sponsor: **Otsuka Pharmaceutical Development & Commercialization, Inc.** · enrollment: 40 (actual)

## Conditions studied

- Atrial Fibrillation
- Paroxysmal Atrial Fibrillation
- Persistent Atrial Fibrillation

## Interventions

- **DRUG:** OPC-108459
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01483183
- **Lead sponsor:** Otsuka Pharmaceutical Development & Commercialization, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-11
- **Primary completion:** 2015-10
- **Final completion:** 2015-10
- **Target enrollment:** 40 (ACTUAL)
- **Why stopped:** Enrollment Difficulty
- **Last updated:** 2017-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01483183

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01483183, "Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01483183. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*